BioSpace News Archive

Samsung Biologics, the world’s leading contract development and manufacturing organization, announced strong financial results for the first quarter of fiscal year 2022.

MannKind Corporation announced that it has presented a poster [Abstract #445] at the 15th International Conference on Advanced Technologies & Treatments for Diabetes held April 27-30 in Barcelona and virtually.

AcureX Therapeutics Corporation, a privately-held preclinical-stage biopharmaceutical company focused on developing potential disease altering therapeutics for neurodegenerative diseases, announced that it was selected to receive a grant from The Michael J. Fox Foundation to accelerate the development of AcureX’s biomarker for use in Parkinson’s disease drug development and clinical trials.

Acutus Medical, Inc. announced a commitment letter from Deerfield Management Company, to refinance its existing debt with a new longer-term credit facility, and in conjunction with the refinancing, a definitive agreement to sell the Company’s left-heart access portfolio to Medtronic.

Clover Biopharmaceuticals, Ltd., a global clinical-stage biotechnology company developing novel vaccines and biologic therapeutic candidates, announced the appointment of Mr. LiongHo Chua as President of Greater China.

Zomedica Corp. announced that Larry Heaton, Chief Executive Officer, will provide a strategic update and discuss first quarter 2022 earnings at the upcoming H.C. Wainwright Global Investment Conference, scheduled for 11:30 am ET on May 24, 2022.

Pfizer Inc. and Biohaven Pharmaceutical Holding Company Ltd. announced that the European Commission has granted marketing authorization for VYDURA®, a calcitonin gene-related peptide receptor antagonist for both the acute treatment of migraine with or without aura, and prophylaxis of episodic migraine in adults who have at least four migraine attacks per month.

Lannett Company, Inc. (NYSE: LCI) today announced that it will report financial results for its fiscal 2022 third quarter on Wednesday, May 4, 2022 , after the market closes.

Battelle launched a weeklong pilot demonstration in early March of its first-to-market total solution for PFAS removal and destruction at a wastewater treatment facility operated by Heritage-Crystal Clean in western Michigan.

WATERTOWN, Mass., April 27, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, May 4, 2022 to report its first quarter 2022 financial results and highlight recent corporate developments.